Mar 19th 2013 - Edison Investment Research today published a report on ArQule entitled "2013 Will Be A Transitional Year". In summary, the report says:
2013 will be a year in which ArQule and its partners are focused on progressing and/or completing clinical trials with tivantinib, but one which sees relatively few new clinical data read-outs. The speed of patient accrual in the recently opened METIV Phase III trial in hepatocellular carcinoma will, however, be an important signal. ArQule’s current up to 30 months target for recruitment could be very conservative. This will determine the timing of the interim analysis, which could come as early as late 2014. The start of a Phase I trial of ARQ 087 brings a new compound into clinical trials, while the future of ARQ 621 and ARQ 736 should soon be decided.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »